Clinical Oncology Pharmacist, Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania Mirtazapine is a tetracyclic antidepressant approved by the US Food and Drug Administration for the treatment ...

Cachexia is a process that accompanies many chronic diseases, and consists of a combination of wasting of lean body mass, increased energy expenditure, and a paradoxical loss of appetite. Cachexia ...

A study describes the generation of a new mouse model that could lead to a better understanding of the cachexia syndrome. A study published in Cell Reports Aug. 6 describes the generation of a new ...

Cachexia is common in cancer, yet it is poorly understood in noncancer diagnoses. In this article, Carlson and Dahlin review cancer cachexia in cardiac disease. The definition, pathophysiology, and ...

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...

In 2011, Laura Beaver did not let the growing tumor in her body dictate her life. She kept up her normal hourlong gym routine. She took weekend bike rides near her Washington state home. She did the ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

Sex Differences in the Return-to-Work Process of Cancer Survivors 2 Years After Diagnosis: Results From a Large French Population-Based Sample Several studies have evaluated the effect of melatonin on ...

A multidisciplinary team of researchers has identified Upd3, a cytokine, as an important modulator of tumor growth and host wasting via activation of JAK/STAT signaling. Cancer therapy has shown ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...